Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06999434
PHASE1
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Sponsor: Yale University
View on ClinicalTrials.gov
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
105
Start Date
2025-05-05
Completion Date
2030-05-05
Last Updated
2025-05-31
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
[ 18F]3F4AP
PET Scan #3
DRUG
[18F]MK6240
PET Scan #2
DRUG
[11C]PIB
PET Scan #1
Locations (1)
Yale University PET Center
New Haven, Connecticut, United States